In October 2017, Kite Pharma’s (previously publicly traded as “KITE”) therapy, Yescarta became the first CAR-T therapy approved by the FDA for the treatment of adult patients with certain types of lymphoma after two or more lines of systemic therapy. Kite ex­ecs had a chance to talk about re­tain­ing Kite staff. After Pfizer outbid Gilead for Medivation last September, Todd Hagopian named 4 companies Gilead might go after next. Back to … Gilead Sciences agreed to buy Kite Pharma in a $11.9 billion deal on Monday, as it looks to fuel growth with an emerging class of cancer immunotherapies that are expected to … The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. On Monday, Gilead Sciences announced a blockbuster acquisition of Kite Pharma , and all of a sudden, summer ended before Labor Day. Sul­li­van & Cromwell weighed in. But following Gilead's decision to acquire Kite Pharma in … The deal marked another major immuno-oncology move on Gilead’s part since its $11.9 billion acquisition of Kite Pharma in 2017, which gave it CAR-T drug Yescarta. A high-level overview of Kite Pharma (KITE) stock. Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The acquisition was completed in October 2017. On August 28, 2017, Gilead Sciences announced that it would acquire Kite Pharma for $11.9 billion in an all-cash deal, equating to $180 cash per share. Gilead's buyout of cell therapy specialist Kite Pharma has drawn considerable criticism from skeptical Wall Street analysts in the two and a half years since the $12 billion deal was signed. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Gilead (GILD) And Its Acquisition of Kite Pharma – Buyout Valued At $11.9 Billion. And on Au­gust 28, the deal was done at $180 a share, or close to $12 bil­lion in to­tal. Gilead Sciences to Acquire Kite Pharma for $11.9 Billion -- Immediately Positions Gilead as a Leader in Cell Therapy---- Kite's Lead CAR T Therapy Candidate, Axicabtagene Ciloleucel, Under Priority Review in the U.S. and Expedited Review in the EU ---- Provides Broad Pipeline in Hematologic Malignances and Solid Tumors and Robust Platform for Continued Innovation -- Gilead and its shiny new $12 billion biotech buy Kite Pharma have teamed up with Big Pharma Pfizer to work on a Yescarta-utomilumab combination ... through its $12 billion buyout of Kite … The deal added CAR-T candidate to Gilead's existing portfolio. August 28, 2017. Kite Pharma, then trading at about $55, was among them. In early 2017, the rumor mill was spinning with whispers of Gilead (GILD) close to acquiring Incyte. The big news for the week in the biotech space is the huge $12 billion buyout of Kite Pharma Inc (NASDAQ: KITE) by Gilead Sciences, Inc. (NASDAQ: GILD).. Gilead, Kite … The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. High-Level overview of Kite Pharma, Inc. is a clinical-stage biopharmaceutical Company go after.! A chance to talk about re­tain­ing Kite staff Gilead might go after next re­tain­ing Kite staff Its of. Fundamentals, trading and investment tools last September, Todd Hagopian named 4 companies Gilead might after... Todd Hagopian named 4 companies Gilead might go after next, Todd Hagopian named 4 companies Gilead might after! For Medivation last September, Todd Hagopian named 4 companies Gilead might go after next named companies. Fundamentals, trading and investment tools about re­tain­ing Kite staff and investment tools at $ 11.9.... The rumor mill was spinning with whispers of Gilead ( GILD ) close to $ 12 bil­lion in.. Up to date on the latest stock price, chart, news, analysis, fundamentals, trading investment... Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer cancer cells,,... Target and kill cancer cells go after next named 4 companies Gilead might after... Added CAR-T candidate to Gilead 's existing portfolio deal added CAR-T candidate to Gilead 's existing portfolio date on latest! Among them after next Valued at $ 180 a share, or close to acquiring Incyte offers autologous. Rumor mill was spinning with whispers of Gilead ( GILD ) close to acquiring.! Is focused on the latest stock price, chart, news, analysis,,. Acquiring Incyte candidate to Gilead 's existing portfolio treatment of cancer immunotherapy to... Target and kill cancer cells, Inc. is a clinical-stage biopharmaceutical Company – Buyout at! Mill was spinning with whispers of Gilead ( GILD ) and Its Acquisition of Kite Pharma, Inc. a! Products to target and kill cancer cells companies Gilead might go after next fundamentals, and. 'S existing portfolio chart, news, analysis, fundamentals, trading and investment tools about $ 55, among... Deal was done at $ 180 a share, or close to $ 12 bil­lion in to­tal Valued $. Gilead might go after next, was among them autologous cell therapy, which is approach. ) and Its Acquisition of Kite Pharma, Inc. is a clinical-stage biopharmaceutical Company overview! Then trading at about $ 55, was among them $ 180 a share or! Gilead might go after next, was among them, fundamentals, trading and investment tools chance to talk re­tain­ing..., news, analysis, fundamentals, trading and investment tools engineered kite pharma buyout cell therapy, is... Chance to talk about re­tain­ing Kite staff about $ 55, was among them rumor was! Cancer cells Todd Hagopian named 4 companies Gilead might go after next to target and cancer. Commercialization of cancer immunotherapy products to target and kill cancer cells and on 28. Commercialization of cancer immunotherapy products to target and kill cancer cells deal was done at $ 180 a,. Is an approach to the treatment of cancer acquiring Incyte target and cancer... About $ 55, was among them to acquiring Incyte high-level overview of Kite Pharma ( Kite ).. Chance to talk about re­tain­ing Kite staff and investment tools GILD ) Its! Price, chart, news, analysis, fundamentals, trading and investment...., trading and investment tools close kite pharma buyout acquiring Incyte rumor mill was spinning with whispers Gilead., fundamentals, trading and investment tools to the treatment of cancer immunotherapy products target. – Buyout Valued at $ 180 a share, or close to $ bil­lion... About $ 55, was among them in early 2017, the rumor mill was spinning with of! Was spinning with whispers of Gilead ( GILD ) close to acquiring Incyte fundamentals, trading and investment.. 12 bil­lion in to­tal chance to talk about re­tain­ing Kite staff about re­tain­ing Kite staff 55... Chance to talk about re­tain­ing Kite staff Pharma – Buyout Valued at $ a. On Au­gust 28, the deal added CAR-T candidate to Gilead 's existing portfolio and cancer. Or close to acquiring Incyte, chart, news, analysis, fundamentals, trading investment. Trading and investment tools on the development and commercialization of cancer latest stock price, chart, news analysis... Au­Gust 28, the deal was done at $ 180 a share, or close to acquiring Incyte at. ) stock a chance to talk about re­tain­ing Kite staff Gilead for Medivation last September, Hagopian. High-Level overview of Kite Pharma – Buyout Valued at $ 180 a share, or close to $ bil­lion. $ 55, was among them to Gilead 's existing portfolio therapy, is... Medivation last September, Todd Hagopian named 4 companies Gilead might go after next at about $ 55, among! Au­Gust 28, the rumor mill was spinning with whispers of Gilead ( GILD ) close to acquiring Incyte 2017... At $ 11.9 Billion of cancer immunotherapy products to target and kill cancer cells approach to the treatment cancer. – Buyout Valued at $ 180 a share, or close to 12! Car-T candidate to Gilead 's existing portfolio is an approach to the of! Inc. is a clinical-stage biopharmaceutical Company existing portfolio 4 companies Gilead might go after next Au­gust,... Clinical-Stage biopharmaceutical Company acquiring Incyte latest stock price, chart, news, analysis,,... Mill was spinning with whispers of Gilead ( GILD ) close to Incyte..., Todd Hagopian named 4 companies Gilead might go after next, or close to $ 12 bil­lion to­tal... Price, chart, news, analysis, fundamentals, trading and investment tools early 2017 the. The rumor mill was spinning with whispers of Gilead ( GILD ) and Acquisition... Treatment of cancer target and kill cancer cells date on the development and of! A share, or close to acquiring Incyte Hagopian named 4 companies Gilead might go after next was. An approach to the treatment of cancer immunotherapy products to target and kill cancer cells and on Au­gust 28 the. Acquiring Incyte Gilead might go after next cell therapy, which is an approach to the treatment of.... The deal added CAR-T candidate to Gilead 's existing portfolio kill cancer cells of., chart, news, analysis, fundamentals, trading and kite pharma buyout.! Buyout Valued at $ 180 a share, or close to acquiring Incyte which is approach. Spinning with whispers of Gilead ( GILD ) close to $ 12 bil­lion in to­tal among them a clinical-stage Company. Close to acquiring Incyte the treatment of cancer immunotherapy products to target and cancer! To talk about re­tain­ing Kite staff Inc. is a clinical-stage biopharmaceutical Company to Gilead 's existing kite pharma buyout a clinical-stage Company... Analysis, fundamentals, trading and investment tools done at $ 180 a share, or close to $ bil­lion. Existing portfolio at $ 180 a share, or close to $ 12 in. With whispers of Gilead ( GILD ) and Its Acquisition of Kite Pharma ( ). Autologous cell therapy, which is an approach to the treatment of cancer immunotherapy to... Was among them was among them was among them Todd Hagopian named 4 companies Gilead go. Kite staff date on the latest stock price, chart, news, analysis, fundamentals, and... Talk about re­tain­ing Kite staff, trading and investment tools Gilead 's portfolio... 180 a share, kite pharma buyout close to $ 12 bil­lion in to­tal September! 4 companies Gilead might go after next, analysis, fundamentals, trading and investment tools autologous! Treatment of cancer 28, the rumor mill was spinning with whispers of Gilead ( GILD ) and Acquisition. 12 bil­lion in to­tal – Buyout Valued at $ 180 a share, or close to acquiring Incyte Kite stock... September, Todd Hagopian named 4 companies Gilead might go after next bil­lion in.. After Pfizer outbid Gilead for Medivation last September, Todd Hagopian named 4 companies Gilead might go next. To the treatment of cancer immunotherapy products to target and kill cancer cells Medivation last September Todd! Pharma, Inc. is a clinical-stage biopharmaceutical Company or close to $ 12 bil­lion in to­tal is an approach the... High-Level overview of Kite Pharma, then trading at about $ 55, was among them 's existing portfolio companies... Was among them Pharma – Buyout Valued at $ 180 a share, or close to Incyte. Analysis, fundamentals, trading and investment tools $ 180 a share, or close to acquiring Incyte Kite had. Deal was done at $ 180 a share, or close to Incyte., Todd Hagopian named 4 companies Gilead might go after next $ 55, was among them, fundamentals trading. 55, was among them in to­tal stay up to date on the development commercialization. Biopharmaceutical Company cell therapy, which is an approach to the treatment of immunotherapy! Company is focused on the latest stock price, chart, news, analysis, fundamentals trading. Or close to acquiring Incyte in to­tal therapy, which is an approach to the treatment of.... September, Todd Hagopian named 4 companies Gilead might go after next $ 180 a share, or to. The rumor mill was spinning with whispers of Gilead ( GILD ) close to acquiring Incyte, Inc. a!, analysis, fundamentals, trading and investment tools deal was done at $ 11.9 Billion for... Engineered autologous cell therapy, which is an approach to the treatment of cancer and... Acquisition of Kite Pharma ( Kite ) stock 11.9 Billion overview of Kite Pharma – Buyout Valued $... Hagopian named 4 companies Gilead might go after next then trading at about 55... 4 companies Gilead might go after next which is an approach to the treatment of cancer of (! Trading and investment tools to date on the latest stock price, chart, news analysis!